Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

Status unconfirmed

Conditions studied: Relapsing Remitting Multiple Sclerosis

In brief

People with multiple sclerosis (MS) often experience problems with cognitive functioning, which can be debilitating and interfere with their daily functioning. However, research has shown that MS disease modifying agents have had some success in treating cognitive problems. The main purpose of this research study is to investigate how well two medicines (alemtuzumab (Campath®) and interferon beta-1a (Rebif®)) work in treating MS-related cognitive problems (e.g., attention, memory, speed of thinking). Participants enrolled will be assessed prior to their first study-related medication dose and re-assessed throughout treatment. It is expected that participants taking Campath® will demonstrate relative stability in cognitive functioning relative to those taking Rebif®. Specifically, the cognitive performance of Rebif® participants will decline somewhat over time, but the cognitive performance of Campath® participants will remain stable.

Key facts

Study ID

NCT00914758

Run by

Washington Neuropsychology Research Group

People needed

1

Starts

2009-03-01

Expected to finish

2011-12-01

Last updated by the study team

2009-06-05

Who can join

Age: 25 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosis of relapsing remitting MS and enrollment in Care-MS II trial
• Non-MS controls must be neurologically healthy (with respect to conditions that impact CNS functioning).
• Participants must be between the ages of 25 and 50.
• Corrected vision of subjects must be no worse than 20/50.
• Participants must have at least 10 years of education.
• Participants must be capable of writing and pressing the buttons on a computer mouse.
• Participants must be capable of understanding and following all test instructions.

You may not qualify if…

• Participants with a history of head injury, seizures, or neurological conditions involving the central nervous system (other than MS for the MS groups).
• Participants with upper extremity dysfunction which prohibits them from using a computer mouse.
• Participants who are colorblind.
• Participants with history of psychosis or other severe mental illness.
• Participants with current alcohol/substance abuse.
• Participants taking medications with potential adverse CNS effects

Where it is running

• The Research and Education Institute of Alta Bates Summit Medical Center — Berkely, California, United States
• Associates In Neurology. PSC — Lexington, Kentucky, United States
• Springfield Neurology Associates, LLC — Springfield, Massachusetts, United States
• Dartmouth Medical School/Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Multiple Sclerosis Center of NE New York, Empire Neurology, PC — Latham, New York, United States
• Multiple Sclerosis Center, University of Rochester Medical Center — Rochester, New York, United States
• MS Center of Greater Washington — Vienna, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.